GlassScriptPhysician profile
Benjamin Edgar Shoemaker
NPI 1811077712
$6,305.14
in general payments reported to CMS, 2019-2025
27 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.53 · 2020: $85.15 · 2021: $3,804 · 2022: $605 · 2023: $468 · 2024: $598 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics International LTD | $3,500.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $536.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $484.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $249.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $222.52 | 2020-2022 | |
| Abbott Laboratories | $220.36 | 2022-2024 | Amplatzer Amulet, Freestyle Libre 3 |
| Exact Sciences Corporation | $158.22 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $145.79 | 2022-2023 | |
| Kvk-Tech, INC. | $136.16 | 2025 | |
| Merck Sharp & Dohme LLC | $116.73 | 2019-2022 | |
| Urovant Sciences INC | $105.79 | 2022 | |
| Glaxosmithkline, LLC. | $56.98 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $49.73 | 2024-2025 | |
| Pfizer INC. | $46.06 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $44.82 | 2024-2025 | Nuzyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $32.59 | 2025 | |
| Dexcom, INC. | $24.75 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $21.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.22 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.47 | 2023 | Jardiance |
| Astellas Pharma US INC | $16.76 | 2025 | Veozah |
| Coopersurgical, INC. | $16.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2019 | |
| Terumo Medical Corporation | $15.56 | 2019 | |
| Amgen INC. | $14.63 | 2024 | Krystexxa |
| Nabriva Therapeutics, Plc | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.